The problem addressed by the present invention is to provide a new intraocular pressure lowering agent and a new agent for treating or preventing glaucoma or ocular hypertension. The present invention also addresses the problem of providing a new use for cyclic phosphatidic acid derivatives and salts thereof. The present invention provides an intraocular pressure lowering agent, a new agent for treating or preventing glaucoma or ocular hypertension, and a ROCK inhibitor that contain as an active ingredient a compound represented by formula (1). (In the formula, R represents linear or branched alkyl group having 1-30 carbon atoms, a linear or branched alkenyl group having 2-30 carbon atoms, or a linear or branched alkynyl group having 2-30 carbon atoms, each group optionally containing a cycloalkane ring or an aromatic ring. X and Y independently represent an oxygen atom or a methylene group, provided that X and Y do not represent a methylene group at the same time. M represents a hydrogen atom or an alkali metal atom.)
An object of the present invention is to provide a therapeutic agent for pulmonary fibrosis which has high therapeutic effect. The invention provides a therapeutic agent for pulmonary fibrosis which comprises, as an active ingredient, a compound represented by the following formula (I):
An object of the present invention is to provide a therapeutic agent for pulmonary fibrosis which has high therapeutic effect. The invention provides a therapeutic agent for pulmonary fibrosis which comprises, as an active ingredient, a compound represented by the following formula (I):
An object of the present invention is to provide a therapeutic agent for pulmonary fibrosis which has high therapeutic effect. The invention provides a therapeutic agent for pulmonary fibrosis which comprises, as an active ingredient, a compound represented by the following formula (I):
wherein R represents a linear or branched alkyl group having 1 to 30 carbon atoms, a linear or branched alkenyl group having 2 to 30 carbon atoms, or a linear or branched alkynyl group having 2 to 30 carbon atoms, which may contain a cycloalkane or aromatic ring; X and Y each independently represent an oxygen atom or a methylene group, provide that X and Y do not simultaneously represent a methylene group; and M represents a hydrogen atom or an alkali metal atom.
[Problem] To safely and efficiently provide padding in which more than 40 wt% kapok fiber is mixed. [Solution] A mixture comprising the following is blended and dried: Tencel and/or other biodegradable fibrous material; and kapok fiber that has been wetted using a suitable method, e.g., immersion in a solution to which a polysaccharide thickener, surfactant, and/or other amphiphilic substance has been added as solute, or immersion in a solution to which alcohol, acetone, hexane, and/or other organic solvent has been added.
D04H 1/58 - Non-tissés formés uniquement ou principalement de fibres coupées ou autres fibres similaires relativement courtes à partir de voiles ou couches composés de fibres ne possédant pas des propriétés cohésives réelles ou potentielles par application, incorporation ou activation de liages chimiques ou thermoplastiques, p. ex. adhésifs
The present invention addresses the problem of providing a therapeutic agent for pulmonary fibrosis that has high therapeutic effect. The present invention provides a therapeutic agent for pulmonary fibrosis that comprises a compound represented by formula (1) as an active ingredient. (In the formula, R represents linear or branched alkyl group having 1-30 carbon atoms, a linear or branched alkenyl group having 2-30 carbon atoms, or a linear or branched alkynyl group having 2-30 carbon atoms, each group optionally containing a cycloalkane ring or an aromatic ring. X and Y independently represent an oxygen atom or a methylene group, provided that X and Y do not represent a methylene group at the same time. M represents a hydrogen atom or an alkali metal atom.)
Provided is a system for monitoring the condition of a metal recovery device. The condition monitoring system comprises a metal recovery device and a control device. The metal recovery device comprises a voltage measurement unit for measuring the voltage between a negative electrode and a positive electrode. The control device comprises a data calculation unit for processing measured voltage data received from the voltage measurement unit. The data calculation unit calculates, as a feature amount, a derivative value on the basis of the voltage data, compares the feature amount against a prescribed threshold value, and when the feature amount is the threshold value or greater, diagnoses the positive electrode as being in a maintenance-required state.
An object of the present invention is to provide crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal. The present invention provides a crystal of a cyclic phosphonic acid sodium salt (2ccPA) represented by formula (1):
C07F 9/6571 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes de phosphore, avec ou sans atomes d'azote, d'oxygène, de soufre, de sélénium ou de tellure, comme hétéro-atomes du cycle comportant des atomes de phosphore et d'oxygène comme uniques hétéro-atomes du cycle
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
An object t of the present invention is to provide crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal. The present invention provides a crystal of a cyclic phosphonic acid sodium salt (2ccPA) represented by formula (1):
C07F 9/6571 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes de phosphore, avec ou sans atomes d'azote, d'oxygène, de soufre, de sélénium ou de tellure, comme hétéro-atomes du cycle comportant des atomes de phosphore et d'oxygène comme uniques hétéro-atomes du cycle
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
An object of the present invention is to provide a new application of bamboo based on new functions. A method for producing a fermented bamboo extract comprises a pulverization step of pulverizing bamboo to obtain bamboo powder, a fermentation step of fermenting the bamboo powder with lactic acid bacteria to obtain a fermented bamboo product, and an extraction step of subjecting the fermented bamboo product to hot water extraction to obtain an extract.
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23P 10/47 - Fabrication de poudres à écoulement libre ou instantanées, c.-à-d. de poudres reconstituées rapidement par l’ajout d’un liquide utilisant des additifs, p. ex. des émulsifiants, des agents mouillants ou des agents liant la poussière
A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p. ex. bambou, blé ou canne à sucre
An object t of the present invention is to proroaide crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal. The present invention provides a crystal of a cyclic phosphonic acid sodium salt (2ccPA) represented by formula (1):
C07F 9/6571 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes de phosphore, avec ou sans atomes d'azote, d'oxygène, de soufre, de sélénium ou de tellure, comme hétéro-atomes du cycle comportant des atomes de phosphore et d'oxygène comme uniques hétéro-atomes du cycle
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention addresses the problem of providing a method for easily preparing a sodium cyclic phosphatidic acid which can be used in foods and drinks. According to the present invention, provided is a method for preparing a sodium cyclic phosphatidic acid, the method comprising: a step for reacting a lysophospholipid and a phospholipase D in an aqueous medium in the presence of sodium salts; and a step for collecting a precipitation or supernatant liquid obtained by adding an ethyl alcohol to the resulting reaction solution.
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
C12P 1/00 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymesProcédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes
C12P 9/00 - Préparation de composés organiques contenant un métal ou un atome autre que H, N, C, O, S ou un halogène
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
11.
Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same
An object of the present invention is to provide a crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal. The present invention provides a crystal of a cyclic phosphonic acid sodium salt (2ccPA) represented by formula (1):
C07F 9/6571 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes de phosphore, avec ou sans atomes d'azote, d'oxygène, de soufre, de sélénium ou de tellure, comme hétéro-atomes du cycle comportant des atomes de phosphore et d'oxygène comme uniques hétéro-atomes du cycle
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
An object of the present invention is to provide a crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal. The present invention provides a crystal of a cyclic phosphonic acid sodium salt (2ccPA) represented by formula (1):
C07F 9/6571 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes de phosphore, avec ou sans atomes d'azote, d'oxygène, de soufre, de sélénium ou de tellure, comme hétéro-atomes du cycle comportant des atomes de phosphore et d'oxygène comme uniques hétéro-atomes du cycle
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Chemical preparations containing NcPA for use in the
manufacture of pharmaceuticals; chemical preparations
containing NcPA for use in the manufacture of cosmetics. Cosmetic preparations containing NcPA. Pharmaceutical preparations; dietary supplements for humans;
dietetic beverages adapted for medical purposes; dietetic
foods adapted for medical purposes; beverages for babies;
food for babies; dietary supplements for animals.
14.
METHOD AND DEVICE FOR TREATING IODINE-CONTAINING ETCHING SOLUTION WHICH CONTAINS Au
The purpose of the present invention is to establish a technique which enables the collection of Au from a used iodine-containing etching solution with a high collection rate and also enables the restoring of the concentration of iodine (I3-) in the etching solution to recover the etching ability of the etching solution. A method for treating a iodine-containing etching solution that contains Au, which comprises electrolyzing the etching solution to collect Au from the etching solution and restore the concentration of iodine (I3-), wherein the electrolysis is carried out while keeping the cathode potential at -0.7 V or more (wherein the reference potential is a potential of a reference electrode Ag/AgCl) and the anode potential at +1.0 V or less (wherein the reference potential is a potential of a reference electrode Ag/AgCl).
This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, cyclic phosphatidic acid or carbacyclic phosphatidic acid.
A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
C07F 9/6571 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes de phosphore, avec ou sans atomes d'azote, d'oxygène, de soufre, de sélénium ou de tellure, comme hétéro-atomes du cycle comportant des atomes de phosphore et d'oxygène comme uniques hétéro-atomes du cycle
The purpose of the present invention is to provide a hair growth agent having an excellent hair-nourishing/hair-growing effect. The present invention provides a hair growth agent comprising cyclic phosphatidic acid or carbacyclic phosphatidic acid as an active ingredient.
A61K 8/55 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant du phosphore
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
A61Q 7/00 - Préparations pour modifier la pousse des cheveux ou des poils
The purpose of the invention is to provide a method that, when recovering a precious metal from an aqueous solution containing a water-soluble sulfur compound and the precious metal by electrolysis, is able to prevent the deposition of the precious metal on surfaces other than the cathode such as the anode or a wall surface of the electrolytic cell, etc. without using a chemical. The essence of this method for recovering a precious metal is that, when recovering the precious metal from an aqueous solution containing a water-soluble sulfur compound and the precious metal by electrolysis, a gas is supplied into the aqueous solution so that the redox potential of the aqueous solution during the electrolysis is -500 mV to +100 mV.
The purpose of the present invention is to provide a therapeutic agent for joint diseases, which has an activity of preventing the destruction of articular cartilages and has a high therapeutic effect. According to the present invention, a therapeutic agent for joint diseases can be provided, which comprises cyclic phosphatidic acid or carbacyclic phosphatidic acid as an active ingredient.
A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, a compound represented by Formula (I): (See Formula I) wherein R represents a linear or branched alkyl group having 1 to 30 carbon atoms, a linear or branched alkenyl group having 2 to 30 carbon atoms, or a linear or branched alkynyl group having 2 to 30 carbon atoms, which may contain a cycloalkane or aromatic ring; X and Y each independently represent an oxygen atom or a methylene group, provide that X and Y do not simultaneously represent a methylene group; and M represents a hydrogen atom or an alkali metal atom.
A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Provided is a novel nerve cell death inhibitor which has an effect of inhibiting delayed nerve cell death caused by transient ischemia. Specifically provided is a drug for inhibiting delayed nerve cell death caused by transient ischemia, which contains cyclic phosphatidic acid or carbacyclic phosphatidic acid or a salt thereof.
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
Provided is a device, which is used when a metal is electrolytically recovered from a metal containing solution. The metal recovering device can realize more reductions in the space saving and the facility load than those of the recovering device known in the art, and can recover the metal for a short time period so that it is extremely excellent in the metal recovering efficiency. The device comprises a columnar or cylindrical rotating cathode rotating on an axis, an anode arranged to confront the rotating cathode, and a net-shaped or porous conductor. The rotating cathode confronting the anode may be constituted to have at least its face portion covered with the conductor. Alternatively, the device may also comprise a columnar or cylindrical rotating cathode rotating on an axis, and an anode arranged to confront the rotating cathode, and the rotating cathode confronting the anode may also be constituted to have at least its face portion pebbled.
